Fig. 1From: Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRelative (percent decrease in monthly migraine days) and absolute (residual monthly migraine days and Headache Impact Test-6 score) response to erenumabBack to article page